Cardiff’s Move Into First-Line mCRC Backed By Data From Discontinued Study

 
• By Joseph Haas

Based on advice from the FDA, Cardiff is testing its PLK1 inhibitor onvansertib in first-line metastatic colorectal cancer; data from a discontinued second-line trial may support the hypothesis.

Metastatic cancer
Cardiff is working to develop the first new therapy for first-line mCRC in 20 years • Source: Shutterstock

More from Clinical Trials

More from R&D